A bioequivalence pivotal study to evaluate TYMLOS
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Abaloparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics; Registrational
- Sponsors Radius Health Inc.
- 02 Nov 2017 The company has scheduled a meeting with the FDA in January 2018 to align on a regulatory pathway for this trial, as reported in a Radius media release.
- 04 May 2017 New trial record